Press Releases April 8, 2026 08:00 PM

Enact to Host First Quarter 2026 Earnings Call May 6th

Enact Holdings Announces Q1 2026 Earnings Release and Conference Call Scheduled for May 6th

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
ACT

Enact Holdings, Inc., a leading U.S. private mortgage insurance provider, will release its Q1 2026 financial results after market close on May 5, 2026, followed by a conference call on May 6th. The company aims to provide investors and analysts with detailed insights on its financial performance and strategic outlook through its earnings release and supporting materials available on its investor relations website.

Enact to Host First Quarter 2026 Earnings Call May 6th
ACT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Enact Holdings will release its Q1 2026 earnings after market close on May 5, 2026.
  • A conference call to review financial results is scheduled for May 6, 2026, at 8:00 a.m. ET, including a live Q&A session.
  • The company provides extensive investor materials online, reflecting transparency and commitment to shareholder communication.

RALEIGH, N.C., April 09, 2026 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) announced it will issue its first quarter earnings release after the market closes on May 5, 2026. Enact will host a conference call to review first quarter 2026 financial results on May 6, 2026 at 8:00 a.m. (ET).

Enact’s earnings release, summary presentation and financial supplement will be available through the company's website, https://ir.enactmi.com, at the time of their release to the public.

Participants interested in joining the call’s live question and answer session are required to pre-register by clicking here to obtain a dial-in number and unique PIN. It is recommended to join at least 15 minutes in advance, although you may register ahead of the call and dial in at any time during the call. If you wish to join the call but do not plan to ask questions, a live webcast of the event will be available on our website, https://ir.enactmi.com/news-and-events/events.

The webcast also will be archived on the company’s website for one year.

About Enact Holdings, Inc.
Enact (Nasdaq: ACT), operating principally through its wholly-owned subsidiary Enact Mortgage Insurance Corporation since 1981, is a leading U.S. private mortgage insurance provider committed to helping more people achieve the dream of homeownership. Building on a deep understanding of lenders' businesses and a legacy of financial strength, we partner with lenders to bring best-in class service, leading underwriting expertise, and extensive risk and capital management to the mortgage process, helping to put more people in homes and keep them there. By empowering customers and their borrowers, Enact seeks to positively impact the lives of those in the communities in which it serves in a sustainable way. Enact is headquartered in Raleigh, North Carolina.

This press release was published by a CLEAR® Verified individual.


Risks

  • Market fluctuations and economic conditions impacting the U.S. mortgage and housing markets could affect Enact’s financial results.
  • Regulatory changes in the mortgage insurance or broader financial services industry may pose risks to ongoing operations.
  • Potential uncertainty regarding loan default rates and credit risk exposure in the mortgage insurance sector given economic dynamics.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026